RFI is pleased to announce that it has entered into a manufacturing, formulation and sales partnership with Ilhwa NA Inc. (Pearl River, N.Y.), a wholly owned U.S. subsidiary of Korea’s groundbreaking ginseng company, Ilhwa Co Ltd. Ilhwa manufactures GS15-4®, a high-absorption ginseng extract utilizing a patented high-yield, enzyme-fermented process. Winner of the Best Botanical 2012 award at Expo West/Engredea, this unique ginseng extract delivers ginseng with higher efficacy, more consistent absorption and an improved taste profile compared to conventional ginseng extracts.
GS15-4, “the 21st Century Ginseng Extract,” is a breakthrough technology (patents pending) using enzyme fermentation to produce a completely balanced ginseng extract in its end-stage metabolite form. Human clinical studies have proven that it provides 15 times higher absorption, four times faster absorption and four times more consistent absorption. GS15-4 will transform how ginseng can be used in the natural ingredient market.
"Ilhwa is excited to establish this partnership with RFI,” said David C. Konn, president of Ilhwa North America. “RFI is a rare company that has created true vertical integration in the natural ingredient market. As the world leader in ginseng science, Ilhwa wanted to find the right partner to work with on this breakthrough in ginseng technology.”
“GS15-4 is a great fit with our current product line, especially our energy, stress and fermented product platforms,” said Jeff Wuagneux, president and CEO of RFI. “In addition, Ilhwa’s single passion for ginseng, its strong clinical science and its high quality manufacturing exemplify RFI’s From Field to Formula® motto.”